Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$4.84

+$0.17 · +3.64%

Aug 21, 4:00 PM ET

TLRY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

62

Undervalued

Momentum

20

Strong Down

Sentiment

33

Bearish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Irwin David Simon
Listed since
Jul 19, 2018
Employees
3,595

Market position

Day range

Current $4.84

52-week range

Current $4.84

Open
$4.72
Previous close
$4.67
Volume
4.25M
0.88× average
Average volume
4.85M
Average daily volume
Market cap
541.27M USD
Beta
1.91
Market reference 1
50-day average
$4.496
+7.65% above average
200-day average
$7.0039
-30.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
786.38M USD
EV / EBITDA
-20.39×
Earnings yield
-19.96%
Free cash flow yield
-16.63%

Profitability & efficiency

Return on equity
-7.59%
Return on assets
-5.26%
Return on invested capital
-3.14%

Financial health

Current ratio
2.21×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends60%-63%-186%-309%Gross margin, FY2022: 18.59%Gross margin, FY2023: 23.43%Gross margin, FY2024: 28.31%Gross margin, FY2025: 29.29%Gross margin, FY2026: 28.45%Operating margin, FY2022: -37.12%Operating margin, FY2023: -218.41%Operating margin, FY2024: -22.15%Operating margin, FY2025: -277.93%Operating margin, FY2026: -6.88%Net margin, FY2022: -75.88%Net margin, FY2023: -231.64%Net margin, FY2024: -31.05%Net margin, FY2025: -266.25%Net margin, FY2026: -13.39%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 18.59%. Gross margin FY2023 23.43%. Gross margin FY2024 28.31%. Gross margin FY2025 29.29%. Gross margin FY2026 28.45%. Operating margin FY2022 -37.12%. Operating margin FY2023 -218.41%. Operating margin FY2024 -22.15%. Operating margin FY2025 -277.93%. Operating margin FY2026 -6.88%. Net margin FY2022 -75.88%. Net margin FY2023 -231.64%. Net margin FY2024 -31.05%. Net margin FY2025 -266.25%. Net margin FY2026 -13.39%.

Income trends

Revenue

915.45M USD-18.77%

Operating income

−63.03M USD+97.99%

Net income

−122.57M USD+95.92%
Income trends across reported periods1.55B USD−150.8M USD−1.85B USD−3.56B USDRevenue, FY2022: 628.37M USDRevenue, FY2023: 844.72M USDRevenue, FY2024: 1.07B USDRevenue, FY2025: 1.13B USDRevenue, FY2026: 915.45M USDOperating income, FY2022: −233.27M USDOperating income, FY2023: −1.84B USDOperating income, FY2024: −238.1M USDOperating income, FY2025: −3.13B USDOperating income, FY2026: −63.03M USDNet income, FY2022: −476.8M USDNet income, FY2023: −1.96B USDNet income, FY2024: −333.8M USDNet income, FY2025: −3B USDNet income, FY2026: −122.57M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 628.37M USD. Revenue FY2023 844.72M USD. Revenue FY2024 1.07B USD. Revenue FY2025 1.13B USD. Revenue FY2026 915.45M USD. Operating income FY2022 −233.27M USD. Operating income FY2023 −1.84B USD. Operating income FY2024 −238.1M USD. Operating income FY2025 −3.13B USD. Operating income FY2026 −63.03M USD. Net income FY2022 −476.8M USD. Net income FY2023 −1.96B USD. Net income FY2024 −333.8M USD. Net income FY2025 −3B USD. Net income FY2026 −122.57M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue915.45M USD1.13B USD1.07B USD844.72M USD628.37M USD
Cost of goods sold655.01M USD796.88M USD770.66M USD646.77M USD511.56M USD
Gross profit260.44M USD330.11M USD304.33M USD197.95M USD116.82M USD
Research and development361K USD389.7K USD865.23K USD918.64K USD1.52M USD
Selling, general, and administrative295.25M USD356.06M USD341.63M USD311.13M USD233.38M USD
Operating expenses323.47M USD3.46B USD542.43M USD2.04B USD350.08M USD
Interest income6.25M USD15.61M USD17.48M USD44.48M USD11.74M USD
Interest expense29.91M USD56.71M USD67.13M USD62.79M USD39.68M USD
Depreciation and amortization19.59M USD183.17M USD172.93M USD175.31M USD154.59M USD
Operating income−63.03M USD−3.13B USD−238.1M USD−1.84B USD−233.27M USD
Net income−122.57M USD−3B USD−333.8M USD−1.96B USD−476.8M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 9 misses, 0 met estimates
Average EPS surprise
-759.24%
11 comparable reports
Latest EPS result
-0.43
Estimate -0.01 · Miss by 3471.43%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.3-0.17-0.63-1.1Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual -1, estimate -0.04, surprise -2400.00%, Miss. Q2 2025, reported Apr 8, 2025: actual -1, estimate -0.4, surprise -150.00%, Miss. Q3 2025, reported Jul 28, 2025: actual 0.2, estimate -0.235, surprise +185.11%, Beat. Q4 2025, reported Oct 9, 2025: actual -0.004, estimate -0.266, surprise +98.50%, Beat. Q1 2026, reported Jan 8, 2026: actual -0.41, estimate -0.14, surprise -192.86%, Miss. Q2 2026, reported Apr 1, 2026: actual -0.24, estimate -0.14, surprise -71.43%, Miss. Q3 2026, reported Jul 28, 2026: actual -0.43, estimate -0.012, surprise -3471.43%, Miss. Q4 2026, reported Oct 8, 2026: actual —, estimate -0.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates292.98M253.49M214M174.51MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 10, 2025: actual 210.95M USD, estimate 216.34M USD, surprise -2.49%, Miss. Q2 2025, reported Apr 8, 2025: actual 185.78M USD, estimate 206.84M USD, surprise -10.18%, Miss. Q3 2025, reported Jul 28, 2025: actual 224.54M USD, estimate 232.23M USD, surprise -3.32%, Miss. Q4 2025, reported Oct 9, 2025: actual 209.5M USD, estimate 204.55M USD, surprise +2.42%, Beat. Q1 2026, reported Jan 8, 2026: actual 217.51M USD, estimate 210.94M USD, surprise +3.11%, Beat. Q2 2026, reported Apr 1, 2026: actual 206.73M USD, estimate 201.35M USD, surprise +2.67%, Beat. Q3 2026, reported Jul 28, 2026: actual 281.71M USD, estimate 246.3M USD, surprise +14.38%, Beat. Q4 2026, reported Oct 8, 2026: actual —, estimate 269.42M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$65.01

1243.18% upside
Past 12 months12-month forecast

Price history unavailable

High $190Average $65.01Low $10.00

Rating distribution

20 ratings
Strong buy00%
Buy525%
Hold1365%
Sell210%
Strong sell00%

TLRY news

Corporate actions

Corporate action history

Stock split

Effective Dec 2, 2025

1:10

Stock split

Effective May 3, 2021

8,381:10,000

TLRY peers

ETFs holding TLRY

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research TLRY

research.disclaimer